Curetis AG, a developer of molecular diagnostics solutions, has been granted a core technology patent by IP Australia, the Australian patent office, for its Unyvero platform technology. The patent, “Reaction Vessel for PCR Device and Method of Performing PCR,” is the first of several core technology patents filed by Curetis. Its claims cover PCR chamber vessels allowing the integrated amplification and detection of DNA sequences. Curetis has submitted patent applications covering this technology in other key regions, including Europe, the United States, and Japan, and company representatives say they expect these additional patents to be granted in the near future. The Company continues to add trial sites and enroll patients for eventual FDA approval of the Unyvero Solution.
“We are extremely pleased that the patent was granted without any restrictions in scope, as it covers a critical and indispensible aspect of our Unyvero platform,” says Gerd Luedke, PhD, Director. Bio-Assay Development, for Curetis. ”This decision supports our claims around a unique and proprietary way of combining endpoint PCR with an array-based detection in a single reaction vessel.”
“Our Unyvero Solution offers an attractive alternative to real-time PCR because it integrates both amplification and detection,” says Oliver Schacht, PhD, CEO, for Curetis. “Unyvero allows for superior multiplexing without increasing the risk of sample cross-contamination.” Read an article on molecular approaches to infectious disease assays authored by Dr. Schacht and published in the January 2014 issue of MLO.
